Trials / Terminated
TerminatedNCT00754312
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Syndax Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNDX-275 |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-02-28
- Completion
- 2009-02-28
- First posted
- 2008-09-17
- Last updated
- 2022-06-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00754312. Inclusion in this directory is not an endorsement.